Dr. Thornton is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
601 Elmwood Ave
Rochester, NY 14642Phone+1 585-275-2542Fax+1 585-273-1255
Education & Training
University of RochesterResidency, Neurology, 1989 - 1991
Oregon Health & Science University (OHSU Health)Residency, Neurology, 1982 - 1985
UCLA-VA Greater Los AngelesInternship, Internal Medicine, 1981 - 1982
University of Iowa Roy J. and Lucille A. Carver College of MedicineClass of 1981
Certifications & Licensure
OR State Medical License 1983 - Present
NY State Medical License 1989 - 2025- American Board of Psychiatry and Neurology Neurology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012
Clinical Trials
- Myotonic Dystrophy and Facioscapulohumeral Muscular Dystrophy Registry Start of enrollment: 2000 Sep 01
- Clinical Efficacy Trial of Mexiletine for Myotonic Dystrophy Type 1 Start of enrollment: 2011 Jun 01
- Establishing Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1) Start of enrollment: 2019 Jan 01
Publications & Presentations
PubMed
- 86 citationsIdentification and Characterization of Modified Antisense Oligonucleotides Targeting DMPK in Mice and Nonhuman Primates for the Treatment of Myotonic Dystrophy Type 1Sanjay K. Pandey, Thurman M. Wheeler, Samantha L. Justice, Aneeza Kim, Husam S. Younis
The Journal of Pharmacology and Experimental Therapeutics. 2015-11-01 - 75 citationsStimulation of myofibrillar synthesis by exercise is mediated by more efficient translation of mRNAStephen Welle, Kirti Bhatt, Charles A. Thornton
Journal of Applied Physiology. 1999-04-01 - 18 citationsMexiletine in Myotonic Dystrophy Type 1: A Randomized, Double-Blind, Placebo-Controlled Trial.Chad Heatwole, Elizabeth Luebbe, Spencer Rosero, Katy Eichinger, William B. Martens
Neurology. 2020-10-12
Press Mentions
Triplet Therapeutics Announces Participation in Natural History Study of Myotonic Dystrophy Type 1August 18th, 2020
Grant Marks Two Decades of NIH Support for Muscular Dystrophy ResearchFebruary 25th, 2019- Finding a Treatment for Postoperative Cognitive DysfunctionOctober 4th, 2017
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
